European Urology Oncology

Slides:

Advertisements

Similar presentations

Volume 61, Issue 2, Pages (August 2014)

Advertisements

From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,

Copyright © 2011 American Medical Association. All rights reserved.

Mortality rates in incident ESRD patients figure 9

Ann Intern Med. 2012;157(7): doi: / Figure Legend:

Volume 58, Issue 1, Pages (July 2010)

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.

by Clarisse Toledo, George Thomas, Jesse D

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

Volume 57, Issue 1, Pages (January 2010)

Role of Active Surveillance for Localized Small Renal Masses

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,

European Urology Oncology

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Systematic Review of the Management of Local Kidney Cancer Relapse

Volume 71, Issue 4, Pages (April 2017)

European Urology Oncology

European Urology Oncology

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis Mohamad B. Sonbol, Belal Firwana, Talal.

Volume 58, Issue 6, Pages (December 2010)

European Urology Oncology

European Urology Oncology

Volume 61, Issue 6, Pages (June 2012)

Volume 68, Issue 6, Pages (December 2015)

Volume 65, Issue 2, Pages (February 2014)

Volume 74, Issue 3, Pages (September 2018)

The predictive value of s-cystatin C for mortality after coronary artery bypass surgery Alain Dardashti, MD, PhD, Shahab Nozohoor, MD, PhD, Lars Algotsson,

Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL,

Volume 59, Issue 1, Pages (January 2011)

Volume 60, Issue 6, Pages (December 2011)

Renal outcomes analysis after endovascular and open aortic aneurysm repair Teresa Martin-Gonzalez, MD, Claire Pinçon, PhD, Adrien Hertault, MD, Blandine.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

European Urology Oncology

European Urology Oncology

Volume 86, Issue 4, Pages (October 2014)

European Urology Oncology

Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.

Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients Fowzia Ibrahim, MSc, Lisa Hamzah, MRCP, Rachael.

Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial Martin Nyberg, Jonas.

Volume 84, Issue 5, Pages (November 2013)

Sergio Bracarda European Urology Supplements

European Urology Oncology

Volume 91, Issue 1, Pages (January 2017)

Epidemiology of Renal Cell Carcinoma

Volume 79, Issue 9, Pages (May 2011)

The Cost to Medicare of Bladder Cancer Care

U-shaped effect of eGFR and mortality

European Urology Oncology

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Estimated Glomerular Filtration Rate Within the Normal or Mildly Impaired Range and Incident Cardiovascular Disease Alon Eisen, MD, Moshe Hoshen, PhD,

European Urology Oncology

Methods for guideline development

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Volume 84, Issue 4, Pages (October 2013)

European Urology Oncology

Volume 80, Issue 12, Pages (December 2011)

Volume 82, Issue 3, Pages (August 2012)

Volume 81, Issue 7, Pages (April 2012)

Volume 76, Issue 6, Pages (September 2009)

Blood lead and chronic kidney disease in the general United States population: Results from NHANES III Paul Muntner, Jiang He, Suma Vupputuri, Josef.

Epidemiology and Demographics of Prostatitis

Jan Roigas European Urology Supplements

European Urology Oncology

Implementing the European Renal Best Practice Guidelines suggests that prediction equations work well to differentiate risk of end-stage renal disease vs.

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

European Urology Oncology

Presentation transcript:

European Urology Oncology Transperitoneal Robot-assisted Partial Nephrectomy with Minimum Follow-up of 5 Years: Oncological and Functional Outcomes from a Single Institution Riccardo Bertolo, Juan Garisto, Julien Dagenais, Daniel Sagalovich, Robert Stein, Khaled Fareed, Tianming Gao, Sherif Armanyous, Amr Fergany, Michael Lioudis, Jihad Kaouk European Urology Oncology DOI: 10.1016/j.euo.2018.06.012 Copyright © 2018 Terms and Conditions

Fig. 1 Cumulative incidence curves for (A) renal cell carcinoma mortality (1.80% at 5 and 7 yr) and other-cause mortality (6.47% at 5 yr, 9.30% at 7 yr); (B) local recurrence (3.61% at 5 yr, 4.16% at 7 yr); and (C) metastasis (3.24% at 5 yr, 4.57% at 7 yr). European Urology Oncology DOI: (10.1016/j.euo.2018.06.012) Copyright © 2018 Terms and Conditions

Fig. 2 Estimated glomerular filtration rate (eGFR) during follow-up. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration formula, after adjusting for age (continuous), gender, and race (white/non-white). * Last follow-up was at a median of 46 mo (interquartile range 30–58). CI = confidence interval. European Urology Oncology DOI: (10.1016/j.euo.2018.06.012) Copyright © 2018 Terms and Conditions

European Urology Oncology DOI: (10.1016/j.euo.2018.06.012) Copyright © 2018 Terms and Conditions

European Urology Oncology DOI: (10.1016/j.euo.2018.06.012) Copyright © 2018 Terms and Conditions

European Urology Oncology DOI: (10.1016/j.euo.2018.06.012) Copyright © 2018 Terms and Conditions

European Urology Oncology DOI: (10.1016/j.euo.2018.06.012) Copyright © 2018 Terms and Conditions